ArticleScientific reports2026
Explainable machine learning identifies features and thresholds predictive of immunotherapy response.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From Molecular Precision to Clinical Practice: A Comprehensive Review of Bispecific and Trispecific Antibodies in Hematologic Malignancies.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
The identification of reliable predictors for immunotherapy response remains a critical challenge in precision oncology. Here, we integrated patient clinical features with DNA and RNA sequencing data derived from 229 melanoma samples. We use 138 melanoma samples to develop and train machine learning models predicting patient treatment response. Feature selection included a univariate Mann-Whitney U-test screen (p < = 0.05) prior to unique tailoring for each model using SHAP. We identify random forest as the optimal classifier, on an independent cohort of 53 melanoma patients. We test the usefulness of the model using additional test data comprising patients with stable disease (n = 15) and non-cutaneous melanoma (n = 23). Using SHAP, we identified features linked to treatment response including mutation features, immune cell-type abundance and LAG3 expression, highlighting the contributions of both tumour intrinsic and extrinsic factors. Further leveraging SHAP we infer potential numerical thresholds for certain features separating good versus poor immunotherapy response. This explainability driven methodology has potential implications for the clinical translation of biomarker discovery and guiding treatment options to enable precision oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.